Back to Search
Start Over
Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients.
- Source :
-
Journal of chemotherapy (Florence, Italy) [J Chemother] 2022 May; Vol. 34 (3), pp. 190-198. Date of Electronic Publication: 2021 Sep 13. - Publication Year :
- 2022
-
Abstract
- The prognosis is poor for relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL) patients. The brentuximab vedotin (Bv) and bendamustine (B) combination has been used as a preferable salvage regimen in R/R cHL patient trials. We retrospectively evaluated response rates, toxicities, and the survival in R/R cHL patients treated with the BvB combination. In a multi-centre real-life study, 61 R/R HL patients received intravenous doses of 1.8 mg/kg Bv on the first day plus 90 mg/m <superscript>2</superscript> B on the first and second days of a 21-day cycle as a second-line or beyond-salvage regimen. Patients' median age at BvB initiation was 33 (range: 18-76 years). BvB was given as median third-line treatment for a median of four cycles (range: 2-11). The overall and complete response rates were 82% and 68.9%, respectively. After BvB initiation, the median follow-up was 14 months, and one- and two-year overall survival rates were 85% and 72%, respectively. Grade 3/4 toxicities included neutropenia (24.6%), lymphopenia (40%), thrombocytopenia (13%), anaemia (13%), infusion reactions (8.2%), neuropathy (6.5%), and others. The BvB combination could be given as salvage regimen aiming a bridge to autologous stem cell transplant (ASCT), in patients relapse after ASCT or to transplant-ineligible patients with manageable toxicity profiles.
- Subjects :
- Antineoplastic Combined Chemotherapy Protocols adverse effects
Bendamustine Hydrochloride adverse effects
Brentuximab Vedotin
Humans
Neoplasm Recurrence, Local drug therapy
Retrospective Studies
Salvage Therapy
Treatment Outcome
Hodgkin Disease drug therapy
Immunoconjugates adverse effects
Subjects
Details
- Language :
- English
- ISSN :
- 1973-9478
- Volume :
- 34
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Journal of chemotherapy (Florence, Italy)
- Publication Type :
- Academic Journal
- Accession number :
- 34514960
- Full Text :
- https://doi.org/10.1080/1120009X.2021.1976912